This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Commercial biotechnology in Latin America: Current opportunities and challenges
Go to paperABSTRACT: The unparalleled growth of commercial biotechnology in…
This chart shows the companies with the successful drug patent challenges from last year. The most successful drug patent challengers in 2012 were Mylan Pharms Inc, Lupin Pharms, Ivax Sub Teva Pharms, Teva Pharms, Perrigo Israel, Teva, Watson Labs Inc Fl, Dr Reddys Labs Ltd, Innopharma Inc, and Mylan Labs. For more infographics, see the DrugPatentWatch Pharmaceutical Innovation Infographics. Do you have a response to […]
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for September 15 | |||||||||||||||||||||||||||||||||
| Tradename | Applicant | Generic Name | Patent Expiration | ||||||
|---|---|---|---|---|---|---|---|---|---|
CELLCEPT | Roche Palo | mycophenolate mofetil hydrochloride | Sep 15, 2013 | ||||||
CRINONE | Watson Labs | progesterone | Sep 15, 2013 | ||||||
PRELAY | Sankyo | troglitazone | Sep 15, 2013 | ||||||
REZULIN | Pfizer Pharms | troglitazone | Sep 15, 2013 | ||||||
*Drugs may be | |||||||||
DrugPatentWatch Infographics |
 Which Patents Cover the Most |
| More infographics » |
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for September 10 | |||||||||||||||||||||
| Tradename | Applicant | Generic Name | Patent Expiration | ||||||
|---|---|---|---|---|---|---|---|---|---|
MYRBETRIQ | Apgdi | mirabegron | Sep 10, 2013 | ||||||
*Drugs may be | |||||||||
DrugPatentWatch Infographics |
 Which Companies Have the Most Active Drug |
| More infographics » |
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for September 9 2013
DrugPatentWatch Serves Your Competitive Intelligence | |||||||||||||||||||||
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for September 10 | |||||||||||||||||||||
| Tradename | Applicant | Generic Name | Patent Expiration | ||||||
|---|---|---|---|---|---|---|---|---|---|
MYRBETRIQ | Apgdi | mirabegron | Sep 10, 2013 | ||||||
*Drugs may be | |||||||||
DrugPatentWatch Infographics |
 How Many Drug Patents Will Expire in the Coming |
| More infographics » |
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for September 7 2013
DrugPatentWatch Serves Your Competitive Intelligence | |||||||||||||||||||||
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for September 2 2013
DrugPatentWatch Serves Your Competitive Intelligence | |||||||||||||||||||||||||||||
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Drug Patent Expirations for September 2013
Tradename
Applicant
Generic Name
Patent Number
Patent Expiration
LUPRON DEPOT
Abbvie Endocrine Inc
leuprolide acetate
5,575,987
Sep 2, 2013
LUPRON DEPOT-PED
Abbott Endocrine
leuprolide acetate
5,575,987
Sep…
I will be helping judge the AUTM Venture Forum again this year. The competition features a $10,000 prize for the first-place startup company, and valuable guidance and exposure for all entrants. Full details on eligibility and benefits are at http://autmventure2014.istart.org/. The deadline for submissions is September 30, 2013.
